CAS: 501014-45-5 - 9-[2-(Tetrahydro-4H-1,3,6,2-dioxazaborocin-2-yl)ethyl]-9H-carbazole
Formula:C18H21BN2O2
InChI:InChI=1S/C18H21BN2O2/c1-3-7-17-15(5-1)16-6-2-4-8-18(16)21(17)12-9-19-22-13-10-20-11-14-23-19/h1-8,20H,9-14H2
InChI key:InChIKey=CNGIVLLERALTLT-UHFFFAOYSA-N
SMILES:O1B(OCCNCC1)CCN2C=3C=CC=CC3C=4C=CC=CC42
- Synonyms:
- 2-(2-(9H-Carbazol-9-yl)ethyl)-1,3,6,2-dioxazaborocane
- 9-[2-(1,3,6,2-dioxazaborocan-2-yl)ethyl]-9H-carbazole
- 9-[2-(Tetrahydro-4H-1,3,6,2-dioxazaborocin-2-yl)ethyl]-9H-carbazole
- 9H-Carbazole, 9-[2-(tetrahydro-4H-1,3,6,2-dioxazaborocin-2-yl)ethyl]-
Brand | Product data | Purity | Price range | Estimated delivery |
---|---|---|---|---|
2-(2-(9H-Carbazol-9-yl)ethyl)-1,3,6,2-dioxazaborocane REF: IN-DA003EYMCAS: 501014-45-5 | - - - | To inquire | Tue 10 Dec 24 | |
2-(2-(9h-Carbazol-9-yl)ethyl)-1,3,6,2-dioxazaborocane REF: 10-F691597CAS: 501014-45-5 | 98% | - - - | Discontinued product | |
2-(2-(9H-Carbazol-9-yl)ethyl)-1,3,6,2-dioxazaborocane REF: 3D-BVA01445CAS: 501014-45-5 | Min. 95% | - - - | Discontinued product |
2-(2-(9H-Carbazol-9-yl)ethyl)-1,3,6,2-dioxazaborocane
CAS:501014-45-5
Formula:
C18H21BN2O2
Molecular weight:
308.1825
Ref: IN-DA003EYM
Undefined size | To inquire |
Estimated delivery in United States, on Tuesday 10 Dec 2024
2-(2-(9h-Carbazol-9-yl)ethyl)-1,3,6,2-dioxazaborocane
CAS:501014-45-5
Purity:
98%
Molecular weight:
308.19000244140625
Ref: 10-F691597
1g | Discontinued | Request information | |
5g | Discontinued | Request information | |
100mg | Discontinued | Request information |
2-(2-(9H-Carbazol-9-yl)ethyl)-1,3,6,2-dioxazaborocane
CAS:501014-45-5
Please enquire for more information about 2-(2-(9H-Carbazol-9-yl)ethyl)-1,3,6,2-dioxazaborocane including the price, delivery time and more detailed …
Formula:
C18H21BN2O2
Purity:
Min. 95%
Molecular weight:
308.2 g/mol
Ref: 3D-BVA01445
1g | Discontinued | Request information | |
5g | Discontinued | Request information | |
100mg | Discontinued | Request information | |
250mg | Discontinued | Request information | |
500mg | Discontinued | Request information |